A LinkedIn post from Saluda Medical highlights the company’s participation in the recent DGS pain congress in Frankfurt, where it engaged with pain specialists and hosted a scientific symposium. The post notes that Saluda presented new clinical data and showcased an evolution of its Evoke® system incorporating EVA™ sensing technology, which is described as a key milestone in its mission.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
For investors, the emphasis on new clinical data and an upgraded platform suggests continuing R&D progress in neuromodulation for pain management, a segment with growing demand and reimbursement interest. Strong engagement with specialist clinicians and faculty at DGS may help drive future adoption and clinical advocacy, potentially supporting long‑term revenue growth and reinforcing Saluda Medical’s competitive position in advanced spinal cord stimulation technologies.